Integrated Analysis Reveals FOXA1 and Ku70/Ku80 as Targets of Ivermectin in Prostate Cancer
This 2022 study investigates ivermectin’s anticancer effects in prostate cancer, identifying FOXA1 and Ku70/Ku80 as direct targets. Ivermectin induces G0/G1 cell cycle arrest, apoptosis, and DNA damage, while suppressing androgen receptor (AR) signaling. It binds to FOXA1, reducing chromatin accessibility of AR signaling and E2F1, leading to inhibited cell proliferation.
June 26, 2025
No Comments